TP53 and hepatocellular carcinoma: There are lots of potential targets that were related with MDM2–p53 axis dysfunction that can be considered to exert anti-HCC properties, all of which have been found to be abnormally changed in tissues of HCC patients, and are correlated with favorable/unfavorable HCC outcomes (Table 1).